Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
0.6814
+0.0435 (6.82%)
Jun 13, 2025, 4:00 PM - Market closed
Unicycive Therapeutics Employees
As of December 31, 2024, Unicycive Therapeutics had 23 total employees, including 22 full-time and 1 part-time employees. The number of employees increased by 9 or 64.29% compared to the previous year.
Employees
23
Change (1Y)
9
Growth (1Y)
64.29%
Revenue / Employee
n/a
Profits / Employee
-$701,870
Market Cap
82.20M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 23 | 9 | 64.29% |
Dec 31, 2023 | 14 | 2 | 16.67% |
Dec 31, 2022 | 12 | 3 | 33.33% |
Dec 31, 2021 | 9 | 8 | 800.00% |
Dec 31, 2020 | 1 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
UNCY News
- 4 days ago - Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis - GlobeNewsWire
- 23 days ago - Unicycive Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 24 days ago - Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders - GlobeNewsWire
- 4 weeks ago - Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 2 months ago - Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia - GlobeNewsWire
- 4 months ago - Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360 - GlobeNewsWire